US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
CA2314893C
(en)
|
1997-12-22 |
2005-09-13 |
Euro-Celtique, S.A. |
Opioid agonist/antagonist combinations
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
MXPA02004293A
(es)
|
1999-10-29 |
2002-10-31 |
Euro Celtique Sa |
Formulaciones de hidrocodona de liberacion controlada..
|
EP1299104B1
(en)
|
2000-02-08 |
2009-05-13 |
Euro-Celtique S.A. |
Tamper-resistant oral opioid agonist formulations
|
EP1337244A4
(en)
|
2000-10-30 |
2006-01-11 |
Euro Celtique Sa |
HYDROCODON FORMULATIONS WITH CONTROLLED RELEASE
|
US8394813B2
(en)
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
ATE345112T1
(de)
*
|
2001-05-11 |
2006-12-15 |
Endo Pharmaceuticals Inc |
Opioid enthaltende arzneiform gegen missbrauch
|
DE60238756D1
(de)
*
|
2001-05-11 |
2011-02-10 |
Endo Pharmaceuticals Inc |
Opioid enthaltende arzneiform gegen missbrauch
|
US7125561B2
(en)
*
|
2001-05-22 |
2006-10-24 |
Euro-Celtique S.A. |
Compartmentalized dosage form
|
DE60219478T2
(de)
|
2001-07-06 |
2008-01-03 |
Endo Pharmaceuticals Inc. |
Orale gabe von 6-hydroxy-oxymorphon als analgetikum
|
ATE376832T1
(de)
*
|
2001-07-06 |
2007-11-15 |
Penwest Pharmaceuticals Co |
Verzögert freisetzende formulierungen von oxymorphon
|
US8329216B2
(en)
*
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
CA2454328C
(en)
*
|
2001-07-18 |
2008-03-18 |
Christopher D. Breder |
Pharmaceutical combinations of oxycodone and naloxone
|
US7141250B2
(en)
*
|
2001-08-06 |
2006-11-28 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing bittering agent
|
US7157103B2
(en)
|
2001-08-06 |
2007-01-02 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing irritant
|
US20030068375A1
(en)
*
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
US7144587B2
(en)
*
|
2001-08-06 |
2006-12-05 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
|
WO2003013433A2
(en)
*
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
US20030044458A1
(en)
*
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US7332182B2
(en)
*
|
2001-08-06 |
2008-02-19 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
|
US7842307B2
(en)
|
2001-08-06 |
2010-11-30 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
|
CA2457361C
(en)
|
2001-08-06 |
2008-11-04 |
Christopher Breder |
Opioid agonist formulations with releasable and sequestered antagonist
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
US7169752B2
(en)
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
DE10141650C1
(de)
|
2001-08-24 |
2002-11-28 |
Lohmann Therapie Syst Lts |
Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
|
CA2459976A1
(en)
*
|
2001-09-26 |
2003-04-03 |
Penwest Pharmaceuticals Company |
Opioid formulations having reduced potential for abuse
|
US20030125347A1
(en)
*
|
2001-11-02 |
2003-07-03 |
Elan Corporation Plc |
Pharmaceutical composition
|
EP2425821B1
(en)
|
2002-04-05 |
2017-05-10 |
Euro-Celtique S.A. |
Pharmaceutical preparation containing oxycodone and naloxone
|
EP2422773A3
(en)
*
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Sequestering subunit and related compositions and methods
|
EP1551402A4
(en)
*
|
2002-09-23 |
2009-05-27 |
Verion Inc |
PHARMACEUTICAL COMPOSITIONS NOT INDUCING ABUSE
|
DE10250088A1
(de)
*
|
2002-10-25 |
2004-05-06 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
EP2218448B1
(en)
|
2002-12-13 |
2015-09-23 |
Durect Corporation |
Oral drug delivery system comprising high viscosity liquid carrier materials
|
US20040224020A1
(en)
*
|
2002-12-18 |
2004-11-11 |
Schoenhard Grant L. |
Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
|
US7524515B2
(en)
*
|
2003-01-10 |
2009-04-28 |
Mutual Pharmaceuticals, Inc. |
Pharmaceutical safety dosage forms
|
US20040202717A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
JP5501553B2
(ja)
*
|
2003-04-21 |
2014-05-21 |
ユーロ−セルティーク エス.エイ. |
同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程
|
US8790689B2
(en)
*
|
2003-04-30 |
2014-07-29 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
ME00276B
(me)
*
|
2003-04-30 |
2011-05-10 |
Purdue Pharma Lp |
Transdermalni dozni oblik otporan na promjene koje sadrže komponentu aktivnog sredstva i komponentu suprotnog sredstva na mjestu koji je ispod sloja aktivnog sredstva
|
US7182955B2
(en)
|
2003-04-30 |
2007-02-27 |
3M Innovative Properties Company |
Abuse-resistant transdermal dosage form
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
US7201920B2
(en)
|
2003-11-26 |
2007-04-10 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of opioid containing dosage forms
|
US20070269505A1
(en)
*
|
2003-12-09 |
2007-11-22 |
Flath Robert P |
Tamper Resistant Co-Extruded Dosage Form Containing An Active Agent And An Adverse Agent And Process Of Making Same
|
US8883204B2
(en)
|
2003-12-09 |
2014-11-11 |
Purdue Pharma L.P. |
Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
|
WO2005097075A2
(en)
|
2004-03-30 |
2005-10-20 |
Euro-Celtique S.A. |
Tamper resistant dosage form comprising an adsorbent and an adverse agent
|
US7404970B2
(en)
*
|
2004-04-13 |
2008-07-29 |
Konec, Inc. |
Pain relief composition, method to form same, and method to use same
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
EP1604667A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
DK1765292T3
(en)
|
2004-06-12 |
2018-01-02 |
Collegium Pharmaceutical Inc |
ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
US20060177380A1
(en)
*
|
2004-11-24 |
2006-08-10 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
US20070231268A1
(en)
*
|
2004-11-24 |
2007-10-04 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
US20080152595A1
(en)
*
|
2004-11-24 |
2008-06-26 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
US20060110327A1
(en)
*
|
2004-11-24 |
2006-05-25 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
MX2007009162A
(es)
*
|
2005-01-28 |
2007-10-23 |
Euro Celtique Sa |
Formas de dosis rsistente al alcohol.
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
EP1695700A1
(en)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
US20070020339A1
(en)
*
|
2005-07-20 |
2007-01-25 |
Pharmorx Inc. |
Compositions and methods for controlling abuse of medications
|
US8497258B2
(en)
|
2005-11-12 |
2013-07-30 |
The Regents Of The University Of California |
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
|
US20070185145A1
(en)
*
|
2006-02-03 |
2007-08-09 |
Royds Robert B |
Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
|
FR2898056B1
(fr)
*
|
2006-03-01 |
2012-01-20 |
Ethypharm Sa |
Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
KR101495146B1
(ko)
|
2006-03-16 |
2015-02-24 |
트리스 파마 인코포레이티드 |
약물 - 이온교환 수지 복합체를 함유하는 변형 방출 제제
|
AU2007238625A1
(en)
*
|
2006-04-14 |
2007-10-25 |
Shire Llc |
Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
|
US20080069891A1
(en)
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
KR20140079441A
(ko)
|
2006-06-19 |
2014-06-26 |
알파마 파머슈티컬스 엘엘씨 |
약제학적 조성물
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
WO2008027442A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Theraquest Biosciences, Llc |
Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
|
EP1897544A1
(en)
*
|
2006-09-05 |
2008-03-12 |
Holger Lars Hermann |
Opioid agonist and antagonist combinations
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
EP2073797A2
(en)
*
|
2006-10-11 |
2009-07-01 |
Alpharma, Inc. |
Pharmaceutical compositions
|
KR20130122023A
(ko)
*
|
2007-02-12 |
2013-11-06 |
디엠아이 바이오사이언시스 인코포레이티드 |
트라마돌의 부작용을 감소시키는 방법
|
NZ579169A
(en)
*
|
2007-02-12 |
2012-05-25 |
Dmi Biosciences Inc |
Treatment of comorbid premature ejaculation and erectile dysfunction using tramadol and a phosphodiesterase (pde) inhibitor
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
AU2014250614B2
(en)
*
|
2007-09-04 |
2016-11-10 |
Alpharma Pharmaceuticals, Llc |
A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
|
WO2009032270A2
(en)
*
|
2007-09-04 |
2009-03-12 |
Alpharma, Inc. |
A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
|
JP2011506319A
(ja)
|
2007-12-06 |
2011-03-03 |
デュレクト コーポレーション |
疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US20100266645A1
(en)
*
|
2007-12-17 |
2010-10-21 |
Alfred Liang |
Pharmaceutical compositions
|
RU2010129907A
(ru)
|
2007-12-17 |
2012-01-27 |
Лабофарм Инк. (CA) |
Лекарственная форма с контролируемым высвобождением, предотвращающая неправильное употребление
|
US8623418B2
(en)
*
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
WO2010003963A1
(en)
*
|
2008-07-07 |
2010-01-14 |
Euro-Celtique S.A. |
Use of opioid antagonists for treating urinary retention
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
WO2010066034A1
(en)
*
|
2008-12-12 |
2010-06-17 |
Paladin Labs Inc. |
Methadone formulation
|
CA2746888C
(en)
|
2008-12-16 |
2015-05-12 |
Labopharm (Barbados) Limited |
Misuse preventative, controlled release formulation
|
JP5886632B2
(ja)
|
2009-03-10 |
2016-03-16 |
ユーロ−セルティーク エス.エイ. |
オキシコドンおよびナロキソンを含む即時放出医薬組成物
|
EP2440210A4
(en)
|
2009-06-12 |
2014-01-29 |
Meritage Pharma Inc |
METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
|
CA2775890C
(en)
*
|
2009-09-30 |
2016-06-21 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
JP6141583B2
(ja)
*
|
2010-02-24 |
2017-06-07 |
シマ ラブス インク. |
濫用耐性製剤
|
NZ700732A
(en)
*
|
2010-05-10 |
2015-08-28 |
Euro Celtique Sa |
Pharmaceutical compositions comprising hydromorphone and naloxone
|
US8927025B2
(en)
|
2010-05-11 |
2015-01-06 |
Cima Labs Inc. |
Alcohol-resistant metoprolol-containing extended-release oral dosage forms
|
US8623409B1
(en)
|
2010-10-20 |
2014-01-07 |
Tris Pharma Inc. |
Clonidine formulation
|
PL2826467T3
(pl)
|
2010-12-22 |
2018-01-31 |
Purdue Pharma Lp |
Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu
|
ES2581323T3
(es)
|
2010-12-23 |
2016-09-05 |
Purdue Pharma Lp |
Formas de dosificación oral sólida resistentes a alteraciones
|
SG191872A1
(en)
|
2011-02-02 |
2013-08-30 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition comprising opioid agonist and sequestered antagonist
|
CA2839123A1
(en)
|
2011-07-29 |
2013-02-07 |
Grunenthal Gmbh |
Tamper-resistant tablet providing immediate drug release
|
DK2736497T3
(da)
|
2011-07-29 |
2017-11-13 |
Gruenenthal Gmbh |
Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
|
EA033256B1
(ru)
*
|
2011-08-18 |
2019-09-30 |
Байоделивери Сайенсиз Интернэшнл, Инк. |
Не вызывающие зависимость двухслойные устройства для трансмукозальной доставки бупренорфина
|
CN103813785B
(zh)
|
2011-09-19 |
2017-02-15 |
奥瑞克索股份公司 |
新的治疗阿片样物质依赖的抗滥用药物组合物
|
US9566241B2
(en)
|
2012-02-21 |
2017-02-14 |
Auburn University |
Buprenorphine nanoparticle composition and methods thereof
|
PL2872121T3
(pl)
|
2012-07-12 |
2019-02-28 |
SpecGx LLC |
Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania
|
MX366159B
(es)
|
2012-11-30 |
2019-07-01 |
Acura Pharmaceuticals Inc |
Liberacion autorregulada de ingrediente farmaceutico activo.
|
AP2015008579A0
(en)
|
2013-02-05 |
2015-07-31 |
Purdue Pharma Lp |
Tamper resistant pharmaceutical formulations
|
AU2014233453A1
(en)
|
2013-03-15 |
2015-10-01 |
Durect Corporation |
Compositions with a rheological modifier to reduce dissolution variability
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
AU2014289187B2
(en)
|
2013-07-12 |
2019-07-11 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
|
KR20160034352A
(ko)
|
2013-07-23 |
2016-03-29 |
유로-셀티큐 에스.에이. |
장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
|
WO2015023675A2
(en)
|
2013-08-12 |
2015-02-19 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded immediate release abuse deterrent pill
|
WO2015065547A1
(en)
|
2013-10-31 |
2015-05-07 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
EA030310B1
(ru)
|
2013-11-13 |
2018-07-31 |
Эро-Селтик С.А. |
Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
|
US9492444B2
(en)
|
2013-12-17 |
2016-11-15 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
US10172797B2
(en)
|
2013-12-17 |
2019-01-08 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
WO2015089530A1
(de)
*
|
2013-12-20 |
2015-06-25 |
G.L. PHARMA GmbH |
Orale darreichungsform mit verzögerter freisetzung enthaltend morphin und naloxon
|
AU2014370085B2
(en)
*
|
2013-12-23 |
2017-10-26 |
Purdue Pharma L.P. |
Opioid antagonist formulations
|
AU2015237723B2
(en)
|
2014-03-26 |
2018-04-26 |
Sun Pharma Advanced Research Company Ltd. |
Abuse deterrent immediate release biphasic matrix solid dosage form
|
CA2955229C
(en)
|
2014-07-17 |
2020-03-10 |
Pharmaceutical Manufacturing Research Services, Inc. |
Immediate release abuse deterrent liquid fill dosage form
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
JP2017531026A
(ja)
|
2014-10-20 |
2017-10-19 |
ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド |
徐放性乱用抑止性液体充填剤形
|
CN107205943A
(zh)
*
|
2014-12-08 |
2017-09-26 |
德威洛克制药有限公司 |
纳洛酮单剂和多层片剂
|
US11103581B2
(en)
|
2015-08-31 |
2021-08-31 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for self-regulated release of active pharmaceutical ingredient
|
US11590228B1
(en)
|
2015-09-08 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine compositions
|
CA2998259A1
(en)
|
2015-09-10 |
2017-03-16 |
Grunenthal Gmbh |
Protecting oral overdose with abuse deterrent immediate release formulations
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|
WO2018119033A1
(en)
*
|
2016-12-20 |
2018-06-28 |
Cima Labs Inc. |
Abuse-resistant and abuse-deterrent dosage forms
|
US11590081B1
(en)
|
2017-09-24 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine tablets
|
EP3965733A4
(en)
|
2019-05-07 |
2023-01-11 |
Clexio Biosciences Ltd. |
ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE
|
US20220062200A1
(en)
|
2019-05-07 |
2022-03-03 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
US11918689B1
(en)
|
2020-07-28 |
2024-03-05 |
Tris Pharma Inc |
Liquid clonidine extended release composition
|